The hospital has outstanding research capabilities and significant characteristics. In the past five years, it has led more than 260 national-level projects, including National Key Research and Development Program of China and the National Natural Science Foundation of China. It has also taken the lead in developing over 10 national industry standards and publishing industry guidelines. The hospital has received 3 national scientific and technological progress awards and more than 10 provincial and ministerial-level awards, including the Beijing Science and Technology Progress Award.

The hospital excels in medical engineering research and collaborates with universities and enterprises. It focuses on the diagnosis and treatment needs of neurological diseases, cutting-edge medical technologies, and international advanced technologies. It actively promotes the research and development of diagnostic and therapeutic technologies, domestic new drugs, high-end medical devices, and domestic substitutions. As one of the first pilot units for "Beijing Medical Science and Technology Innovation and Achievement Transformation Reform," the hospital is dedicated to building national strategic strength in the field of neurology, leveraging its technological advantages to achieve breakthroughs from "0 to 1." Its internationally pioneering non-disabling cerebrovascular disease high-risk warning model addresses 50% of the world's cerebrovascular disease diagnosis issues, potentially reducing recurrent cerebrovascular diseases by 740,000 cases annually in China and saving RMB 15 billion in medical expenses (based on the prevalence rate). The reverse drug development model has shortened drug development cycles by seven years, leading to the industrialization of four innovative drugs for cerebrovascular diseases, including PDE3A antagonists. The hospital has also established the world's largest international neurosystem disease artificial intelligence research center, developing a series of artificial intelligence products for clinical diagnosis and treatment of neurological diseases. In the past five years, the hospital has been granted more than 180 patents, with a cumulative conversion amount exceeding 2 billion yuan.

In 2020, the hospital received funding as one of the first demonstration units for research-oriented ward construction in Beijing. To date, there are 25 professionals registered for drug clinical trials and 54 principal investigators, as well as 30 professionals registered for medical device clinical trials and 122 principal investigators. The total number of clinical trial projects has continuously increased in the past five years, with an average annual growth rate of over 10%. In 2022, 28% of the clinical trial projects undertaken by the hospital were as lead coordinating units for national multicenter trials. The research-oriented ward has established a "Trial Project Data Quality Management System" and a "Clinical Trial Data Center" system, forming an integrated clinical research management platform tailored to research-oriented wards. This platform improves data collection efficiency and data quality for clinical trials, aligning clinical and research work and enhancing the hospital's clinical trial management capabilities.

Currently, the hospital has three national-level medical centers, six provincial and ministerial-level key laboratories, six provincial and ministerial-level engineering technology research centers, and two Beijing international science and technology cooperation bases.